tailored linker-payloads and design features) that has the potential to generate first-in-class products for difficult to treat solid tumours for patient benefit and promising to succeed where ADCs have failed to make an impact.
April 17, 2023, 1:30 p.m. – 5:00 p.m. ET This study demonstrates that cetuximab, a human IgG1 antibody targeting epidermal growth factor receptor (EGFR) approved for the treatment of colorectal and head and neck canc...
Title:EDB+FN is an attractive therapeutic target in oncology: Insights from protein expression analysis of solid tumors Session Category:Tumor Biology Session Title:The Tumor Microenvironment as a Drug Target Session Date and Time:Monday, April 8, 2024, 1:30 PM - 5:00 PM Location:Poster Section...
Details of the recentAACR 2023poster are as follows: Poster Title and Number:Rationale for the development of a differentiated Trop2 ADC (#6297) Session Category and Title:Chemistry/ Experimental and Molecular Therapeutics; Growt...
2023 04/21 丰硕创投 媒体 + 分享 丰硕创投 A- A+ CD25靶向适体-药物偶联物(CD25-ApDC)选择性地消耗和阻断调节性T细胞。 由于字数过多,分两篇发表,合集(一)摘要编号范围为383-3942,所有编号无英文字母。合集(二)摘要编号范围为3995-LB246,所有涉及英文字母的编号都在此。 Abstract 3995: Trastuzumab derux...